Literature DB >> 12920485

99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes.

Francesco Scopinaro1, Giuseppe De Vincentis, Alexandra D Varvarigou, Cesare Laurenti, Francesco Iori, Silvia Remediani, Stella Chiarini, Salvatore Stella.   

Abstract

Biopsy is the standard method for the diagnosis of prostate cancer; however, it is inadequate for the assessment of lymph node invasion. Radionuclide imaging might be useful for both diagnosis and N staging, but it requires high uptake of radiotracers in order to overcome difficulties arising from the anatomy of the region. The aim of this study was to assess whether or not technetium-99m labelled bombesin (99mTc-BN) scan is able to detect prostate cancer and invasion of pelvic lymph nodes. Ten patients were studied with 99mTc-BN, transrectal ultrasonography, biopsy, computed tomography and magnetic resonance imaging. All the patients with cancer were operated on. Planar dynamic scintigraphy and single-photon emission tomography (SPET) were performed after administration of 185 MBq 99mTc-BN. Two patients showed benign adenoma and eight showed cancer at biopsy. The average Gleason's score was 7.5+/-1.3. 99mTc-BN dynamic planar scan showed hot spots in the prostatic fossa in two of the eight patients with cancer, both of whom had a prostate-specific antigen level higher than 20 ng/ml. In these patients, high uptake inside the prostatic fossa was detected as early as 1 min after injection, before the arrival of radioactivity in the bladder. True positive SPET scans were obtained in all eight patients with cancer. Invasion of the obturator nodes was detected by SPET in three patients, and in all three was confirmed at surgery. Our preliminary data encourage further studies on the prostate with 99mTc-BN. If the high sensitivity of 99mTc-BN SPET is confirmed, this method may play an important role in diagnosing and staging prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920485     DOI: 10.1007/s00259-003-1261-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  7 in total

1.  Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study.

Authors:  C Van de Wiele; F Dumont; R Vanden Broecke; W Oosterlinck; V Cocquyt; R Serreyn; S Peers; J Thornback; G Slegers; R A Dierckx
Journal:  Eur J Nucl Med       Date:  2000-11

2.  Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy.

Authors:  Soo-Jeon Park; Hideaki Miyake; Isao Hara; Hiroshi Eto
Journal:  Int J Urol       Date:  2003-02       Impact factor: 3.369

3.  Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide.

Authors:  A D Varvarigou; F Scopinaro; L Leondiadis; V Corleto; O Schillaci; G De Vincentis; T G Sourlingas; K E Sekeri-Pataryas; G P Evangelatos; A Leonti; S Xanthopoulos; G Delle Fave; S C Archimandritis
Journal:  Cancer Biother Radiopharm       Date:  2002-06       Impact factor: 3.099

4.  Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients.

Authors:  F Scopinaro; A D Varvarigou; W Ussof; G De Vincentis; T G Sourlingas; G P Evangelatos; J Datsteris; S C Archimandritis
Journal:  Cancer Biother Radiopharm       Date:  2002-06       Impact factor: 3.099

5.  Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer.

Authors:  M R Feneley; H Jan; M Granowska; S J Mather; D Ellison; J Glass; M Coptcoat; R S Kirby; C Ogden; R T D Oliver; D F Badenoch; F I Chinegwundoh; V H Nargund; A M I Paris; K E Britton
Journal:  Prostate Cancer Prostatic Dis       Date:  2000-07       Impact factor: 5.554

6.  Breast cancer takes up 99mTc bombesin. A preliminary report.

Authors:  F Scopinaro; A Varvarigou; W Ussof; G De Vincentis; S Archimandritis; G Evangelatos; V Corleto; A Pulcini; F Capoccetti; S Remediani; R Massa
Journal:  Tumori       Date:  2002 May-Jun

7.  Phase I trial of technetium [Leu13] bombesin as cancer seeking agent: possible scintigraphic guide for surgery?

Authors:  G De Vincentis; F Scopinaro; A Varvarigou; W Ussof; O Schillaci; S Archimandritis; V Corleto; F Longo; G Delle Fave
Journal:  Tumori       Date:  2002 May-Jun
  7 in total
  23 in total

Review 1.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

Review 2.  Radiolabeled bombesin derivatives for preclinical oncological imaging.

Authors:  Carolina de Aguiar Ferreira; Leonardo Lima Fuscaldi; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2016-12-29       Impact factor: 6.529

3.  Correlation of the Ga-68-bombesin analog Ga-68-BZH3 with receptors expression in gliomas as measured by quantitative dynamic positron emission tomography (dPET) and gene arrays.

Authors:  Ludwig G Strauss; Dirk Koczan; Marcel Seiz; Jochen Tuettenberg; Kirsten Schmieder; Leyun Pan; Caixia Cheng; Antonia Dimitrakopoulou-Strauss
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

Review 4.  Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.

Authors:  Lucia Baratto; Hossein Jadvar; Andrei Iagaru
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

Review 5.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

6.  A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.

Authors:  Kubra Durkan; Zongrun Jiang; Tammy L Rold; Gary L Sieckman; Timothy J Hoffman; Rajendra Prasad Bandari; Ashley F Szczodroski; Liqin Liu; Yubin Miao; Tamila Stott Reynolds; Charles J Smith
Journal:  Nucl Med Biol       Date:  2013-11-28       Impact factor: 2.408

7.  Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA.

Authors:  Beatrice Waser; Véronique Eltschinger; Karen Linder; Adrian Nunn; Jean Claude Reubi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-15       Impact factor: 9.236

Review 8.  Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm.

Authors:  Hebert Alberto Vargas; Jan Grimm; Olivio F Donati; Evis Sala; Hedvig Hricak
Journal:  Eur Radiol       Date:  2015-02-20       Impact factor: 5.315

Review 9.  Targeting GRPR in urological cancers--from basic research to clinical application.

Authors:  Rosalba Mansi; Achim Fleischmann; Helmut R Mäcke; Jean C Reubi
Journal:  Nat Rev Urol       Date:  2013-03-19       Impact factor: 14.432

10.  In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues.

Authors:  Regi Thomas; Jianqing Chen; Martine M Roudier; Robert L Vessella; Laura E Lantry; Adrian D Nunn
Journal:  Clin Exp Metastasis       Date:  2008-10-31       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.